Stefan Deneberg

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BLOOD ADVANCES. 2024;8(3):571-580

Clinical and immunological features in ACKR1/DARC-associated neutropenia

Palmblad J; Sohlberg E; Nilsson CC; Lindqvist H; Deneberg S; Ratcliffe P; Meinke S; Mortberg A; Klimkowska M; Hoglund P
Article: BLOOD. 2023;142(1):73-89

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Article: HAEMATOLOGICA. 2023;108(4):1015-1025

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications

Nilsson C; Linde F; Hulegardh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jadersten M; Bjorkvall CK; Mollgard L; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940

Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial

Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Article: HAEMATOLOGICA. 2022;107(7):1528-1537

A risk score based on real-world data to predict early death in acute promyelocytic leukemia

Osterroos A; Maia T; Eriksson A; Jadersten M; Lazarevic V; Wennstrom L; Antunovic P; Cammenga J; Deneberg S; Lorenz F; Mollgard L; Uggla B; Olander E; Aguiar E; Trigo F; Hoglund M; Juliusson G; Lehmann S
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study

Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf A; Deneberg S; Jadersten M; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Olander E; Ehinger M; Fogelstrand L; Hoglund M; Lazarevic VL
Article: GENES CHROMOSOMES & CANCER. 2021;60(6):426-433

Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study

Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Hoglund M; Lehmann S; Derolf A; Deneberg S; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Lilljebjorn H; Rissler M; Fioretos T; Lazarevic VL
Article: LEUKEMIA. 2021;35(1):62-74

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Montesinos P; Roboz GJ; Bulabois C-E; Subklewe M; Platzbecker U; Ofran Y; Papayannidis C; Wierzbowska A; Shin HJ; Doronin V; Deneberg S; Yeh S-P; Ozcan MA; Knapper S; Cortes J; Pollyea DA; Ossenkoppele G; Giralt S; Doehner H; Heuser M; Xiu L; Singh I; Huang F; Larsen JS; Wei AH
Article: BLOOD. 2020;136(3):339-352

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding

Mujahed H; Miliara S; Neddermeyer A; Bengtzen S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Article: BLOOD ADVANCES. 2020;4(6):1094-1101

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Juliusson G; Jadersten M; Deneberg S; Lehmann S; Mollgard L; Wennstrom L; Antunovic P; Cammenga J; Lorenz F; Olander E; Lazarevic VL; Hoglund M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(5):493-500

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry

Lazarevic VL; Rosso A; Juliusson G; Antunovic P; Derolf AR; Deneberg S; Mollgard L; Uggla B; Wennstrom L; Wahlin A; Hoglund M; Lehmann S; Johansson B
Article: EPIGENETICS. 2014;9(8):1108-1119

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes

Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzen S; Hoglund M; Bullinger L; Doehner K; Lehmann S
Article: EPIGENETICS. 2014;9(6):910-917

microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia

Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15

A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis

Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Article: BLOOD. 2011;118(20):5573-5582

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks

Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzen S; Nahi H; Uggla B; Tidefelt U; Hoglund M; Paul C; Ekwall K; Doehner K; Lehmann S
Article: LEUKEMIA. 2011;25(7):1128-1134

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry

Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Mollgard L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennstrom L; Hoglund M; Juliusson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;86(3):206-215

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

Ali D; Jonsson-Videsater K; Deneberg S; Bengtzen S; Nahi H; Paul C; Lehmann S
Article: LEUKEMIA. 2010;24(5):932-941

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia

Deneberg S; Grovdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Doehner K; Paul C; Ekstrom TJ; Hellstrom-Lindberg E; Lehmann S
Article: HAEMATOLOGICA. 2009;94(9):1301-1306

Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells

Akagi T; Shih L-Y; Ogawa S; Gerss J; Moore SR; Schreck R; Kawamata N; Liang D-C; Sanada M; Nannya Y; Deneberg S; Zachariadis V; Nordgren A; Song JH; Dugas M; Lehmann S; Koeffler HP
Article: LEUKEMIA & LYMPHOMA. 2009;50(9):1512-1518

Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival

Paul E; Uggla B; Deneberg S; Bengtzen S; Hermansson M; Dahlman I; Rosenquist R; Wiman KG; Nahi H
Article: ONCOLOGY REPORTS. 2009;22(1):137-142

Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation

Paul E; Sutlu T; Deneberg S; Alici E; Bjorkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62(3):439-448

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia

Mollgard L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsater K; Fioretos T; Andersson A; Paul C; Lehmann S
Article: JOURNAL OF RHEUMATOLOGY. 2007;34(9):1810-1816

Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis -: A randomized study

Hafstrom I; Rohani M; Deneberg S; Wornert M; Jogestrand T; Frostegard J
Visa fler

Alla övriga publikationer

Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971

Omalizumab alleviates pruritus in myeloproliferative neoplasms

Landtblom AR; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jadersten M
Letter: LEUKEMIA. 2021;35(8):2416-2418

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI

Richter J; Lubking A; Soderlund S; Lotfi K; Markevarn B; Sjalander A; Stenke L; Deneberg S; Ahlstrand E; Myhr-Eriksson K; Panayiotidis P; Gedde-Dahl T; Zackova D; Mayer J; Olsson-Stromberg U; Mahon F-X; Saussele S; Hjorth-Hansen H; Koskenvesa P
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):e13-e16

Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years

Osterroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Mollgard L; Derolf AR; Uggla B; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(1):187-191

Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor

Derolf A; Juliusson G; Benson L; Floisand Y; Lazarevic V; Antunovic P; Mollgard L; Lehmann S; Uggla B; Wahlin A; Hoglund M; Deneberg S
Letter: BLOOD. 2019;134(18):1558-1561

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

Juliusson G; Hagberg O; Lazarevic VL; Olander E; Antunovic P; Cammenga J; Wennstrom L; Mollgard L; Brune M; Jadersten M; Deneberg S; Lehmann S; Derolf AR; Hoglund M
Letter: HAEMATOLOGICA. 2018;103(12):e578-e580

Acute myeloid leukemia in very old patients

Lazarevic VL; Bredberg A; Lorenz F; Ohlander E; Antunovic P; Cammenga J; Wennstrom L; Mollgard L; Deneberg S; Derolf A; Hoglund M; Juliusson G
Letter: LEUKEMIA. 2017;31(6):1457-1459

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013

Lehmann S; Deneberg S; Antunovic P; Rangert-Derolf A; Garelius H; Lazarevic V; Myhr-Eriksson K; Mollgard L; Uggla B; Wahlin A; Wennstrom L; Hoglund M; Juliusson G
Letter: BLOOD CANCER JOURNAL. 2016;6(7):e447

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Deneberg S; Cherif H; Lazarevic V; Andersson P-O; von Euler M; Juliusson G; Lehmann S
Review: METHODS IN MOLECULAR BIOLOGY. 2012;863:119-137

Epigenetics in myeloid malignancies.

Deneberg S
Thesis / dissertation: 2011

Prognostic and biological implications of epigenetic changes in leukemia

Deneberg, Stefan
Meeting abstract: BLOOD. 2007;110(11):133B

Expression of p14ARF in de novo AML with normal karyotype.: Implication on drug resistance and survival

Paul EO; Deneberg S; Lehmann S; Bengtzen S; Nahi H
Editorial comment: MEDICAL ONCOLOGY. 2007;24(3):354-356

Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease.: Implications for its use?

Deneberg S; Lerner R; Ljungman P; Ringden O; Hagglund H

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2012

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI